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Multidrug resistance-associated protein (MRP1) may function as a floppase in human red blood cells to translocate phosphatidylserine
and/or phosphatidylcholine from inner membrane leaflet to outer leaflet. Here we report that the purified and reconstituted MRP1 protein into
asolectin proteoliposomes is mainly in an inside–out configuration and possesses the ability to flop a fluorescent labeled phosphatidylcholine
(NBD-PC) from outer leaflet (protoplasmic) to inner leaflet (extrocytoplasmic). The reconstituted MRP1 protein retains endogenous ATPase
activity. ATP hydrolysis is required for the flopping since removal of ATP and/or Mg2 + inhibits the translocation of NBD-PC. Further
evidence to support this conclusion is that the translocation of NBD-PC is inhibited by vanadate, which traps ATP hydrolysis product ADP in
the nucleotide binding domains. In addition, the translocation of NBD-PC by proteoliposomes containing MRP1 protein is in a glutathione-
dependent manner, similar to the process of translocating anticancer drugs such as daunorubicin. verapamil, vincristine, vinblastine,
doxorubicin and oxidized glutathione partially inhibited the translocation of NBD-PC, whereas MK 571, an inhibitor of MRP1 protein,
inhibited the translocation almost completely. Taken together, the purified and reconstituted MRP1 protein possesses the ability to flop NBD-
PC from outer to inner leaflet of the proteoliposomes.
D 2003 Elsevier B.V. All rights reserved.Keywords: MRP1; Floppase; NBD-PC1. Introduction
Overexpression of P-glycoprotein (Pgp) and/or multi-
drug resistance-associated protein (MRP1) in cancer cells
confers multidrug resistance [1–4]. Pgp is a 170 kDa
membrane-bound glycoprotein with two transmembrane
domains (TMD) and two nucleotide binding domains
(NBD) [5–8]. MRP1 is a 190 kDa membrane-bound
glycoprotein with similar core structure as Pgp, but with
an extra TMD and a linker region at the N-terminus [4,9–
11]. Therefore, both of them are members of the ATP
binding cassette (ABC) superfamily of transport systems
with two typical NBDs coupling ATP binding/hydrolysis
to drug transport. Although the drug resistance profiles
exerted by these two proteins are somewhat similar, they
pump solutes out of cells in different fashions, i.e., Pgp0005-2736/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2003.11.010
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E-mail address: huang@sun5.ibp.ac.cn (Y. Huang).transports hydrophobic compounds out of the cells directly
[12–14], whereas MRP1 transports anionic conjugates,
such as glutathione, glucuronate, or sulfate-conjugated
aliphatic, prostanoid or heterocyclic compounds [15–23].
Common feature is that both of them actively transport a
wide range of compounds with different structures and
functions. One question has been asked is whether they
translocate the components of the membrane bilayer where
they reside. A bacterial ABC transporter, MsbA, a homo-
log of mammalian Pgp, had been proposed to transport
nascent core-lipid A molecule across the inner membrane
[24] and is responsible for the translocation of lipid A to
the outer membrane [25]. Yeast ABC transporters, Pdr5p
and Yor1p, are responsible for the translocation of a
fluorescent-labeled phosphatidylethanolamine (PE) ana-
logue, C6-NBD-PE (C6-2-(12-(7-nitrobenz-2-oxa-(1,3-
diazol-4-yl)amino)dodecanoyl-1-hexade-canoyl-sn-glycero-
3-phosphatidylethanolamine), since cells lacking the genes
coding for these proteins showed increased levels of
accumulation of the fluorescent derivatives [26]. Mouse
Mdr1, human MDR1 and MDR3 can translocate short
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mouse canalicular membrane plays an important role in
the excretion of phospholipid into bile [28,29] since there
is virtually no phospholipid secretion into canaliculus in
Mdr2 knocked out mice [30]. Mouse Mdr2 expression in
yeast secretory vesicles caused translocation of a fluores-
cent-labeled PC from outer to inner leaflet of the mem-
brane [31]. All these results indicate that Pgp, no matter
whether it comes from bacteria, yeast, mouse or human,
can translocate the components of membrane bilayer where
they reside. Direct evidence comes from the Pgp recon-
stituted into proteoliposomes in which it translocates a
wide variety of NBD-lipids from the outer to the inner
leaflet of the bilayer [32]. Whether MRP1 protein has a
similar function as Pgp to translocate the components of
the membrane bilayer where it resides has also been
proved. MRP1 protein seems likely to translocate the
fluorescent-labeled PC, phosphatidylserine, sphingomyelin
and glucosylceramide from inner to outer leaflet across the
plasma membrane of eukaryotic cells [33–36]. However,
since those experiments were performed in intact cells, it
was uncertain whether MRP1 alone or along with other
factors had the ability to translocate the phospholipids. To
test this, we have purified MRP1 protein, reconstituted it
into proteoliposomes and investigated the translocation of
a fluorescent-labeled PC analogue, 1-palmitoyl-2-[6-[(7-
nitro-2-1,3-benzoxadiazol-4-yl)amino]caproyl]-sn-glycero-
3-phosphocholine (NBD-PC) by using the protocols estab-
lished [32,37]. Our results indicated that the reconstituted
MRP1 protein in proteoliposomes translocated NBD-PC
from the outer leaflet to inner leaflet of the membrane
bilayer in an ATP-, Mg2 +- and glutathione-dependent
manner. Therefore, MRP1 alone appears to be able to
translocate NBD-PC from one leaflet of the bilayer to the
other.2. Materials and methods
2.1. Materials
NBD-PC was purchased from Avanti Polar Lipids
(Alabaster, AL). Asolectin, sodium dithionite, ATP,
CHAPS, Triton X-100, vinblastine, vincristine, doxorubi-
cin, daunorubicin and verapamil were purchased from
Sigma Chemical Co. 3-([{3-(2-[7-chloro-2-quinolinyl]
thenyl) phenyl}-{(3-dimethylamino-3-oxopropyl) thio}-
methyl] thio) propanoic acid (MK-571) was provided
generously by Dr. A.W. Ford-Hutchinson (Merck Frosst
Centre for Therapeutic Research, Pointe Claire-Dorval,
Quebec, Canada). The other reagents were analytical grade.
2.2. Purification of MRP1 protein
A baby hamster kidney cell line stably expressing human
MRP1/His was utilized for the purification of MRP1 protein[38]. Cells expressing MRP1/His were cultured at 37 jC in
5% CO2 in the presence of 100 AM methotrexate. Mem-
brane vesicles were prepared according to the published
procedures [38]. Membrane vesicles were solubilized in a
buffer A (20 mM Tris–HCl, pH 7.9, and 500 mM NaCl)
containing 5 mM imidazole, 10 mM CHAPS and 20% (v/v)
glycerol. The solubilized sample was sonicated and insolu-
ble material was removed by centrifugation at 10,000 g
for 15 min [38]. The supernatant was applied on to a
His.Bind Resin column, which was pre-equilibrated in
buffer A, followed by three washes with six column
volumes of buffers: first wash with buffer A containing 5
mM CHAPS and 25 mM imidazole; second wash with
buffer A containing 5 mM CHAPS, 10% glycerol, and 40
mM imidazole; and the third wash with buffer containing 20
mM Tris–HCl (pH 7.4), 500 mM NaCl, 5 mM CHAPS and
40 mM imidazole. The protein was eluted with two column
volumes of buffer containing 20 mM Tris–HCl (pH 7.4), 5
mM CHAPS, 0.05% h-mercaptoethanol and 300 mM im-
idazole. The eluate was dialyzed extensively against 50
volumes of buffer containing 5 mM Tris–HCl (pH 7.4), 5
mM CHAPS, 500 mM NH4Cl and 0.05% h-mercaptoetha-
nol in a cold room. The purified MRP1 protein was stored
at  80 jC after being ultrafiltrated.
2.3. Reconstitution of MRP1 protein
Purified MRP1 protein was reconstituted into proteoli-
posomes as described previously [32,39]. Briefly, 5 mg of
asolectin and 15 Ag of NBD-labeled PC (dissolved in a 4:1
(v/v) CHCl3/MeOH mixture) were dispensed into a glass
tube, dried under a nitrogen stream and further dried under
vacuum for 2 h to remove the remaining trace of organic
solvent. The dried lipids were then resuspended at a con-
centration of 20 mg/ml in the reconstitution buffer contain-
ing 50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM
dithiothreitol (DTT) and 1 mM MgCl2. The lipid suspension
was sonicated for 45 min in a bath-type sonicator at room
temperature and then stored in aliquots at  80 jC. The
purified MRP1 protein was reconstituted as following: 200
Al of the stored lipid aliquot (4 mg asolectin) and 100 Al 30%
(w/v) CHAPS were mixed in an eppendorf tube and then
500 Ag of the purified MRP1 protein in 700 Al of the
reconstitution buffer containing 15 mM CHAPS was added
to the lipid/detergent solution. After periodic mixing on ice
for 1 h, CHAPS was removed by passing the mixture
through a reconstitution buffer pre-equilibrated Sepharose
CL-4B column (115 cm). Turbid fractions were collected
and the reconstituted MRP1 proteoliposomes were har-
vested by centrifugation at 145,000 g for 1 h at 4 jC.
The proteoliposomes were resuspended in 200 Al of trans-
port buffer (50 mM Tris–HCl, pH 7.5, 250 mM sucrose, 5
mM MgCl2) for measurement of NBD-PC translocation.
The final lipid/protein ratio of the reconstituted proteolipo-
somes should be in the range of 10:1 to 15:1 (w/w).
Proteoliposomes were homogenized by passing through a
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 80 jC.
2.4. Electron microscopy
To observe proteoliposomes by negative staining, 5
Al of the proteoliposomes (0.5 mg lipid/ml) with or
without NBD-PC were adsorbed onto a carbon-coated
copper grid. After 1 min, the droplet was removed with
filter paper and for negative staining, 5 Al of 2% uranyl
acetate, pH 4.5, applied to the grid. After 50 s, the droplet
was adsorbed with filter paper. The grid was allowed to
air dry and was examined in a PHILIPS TECNAI 20
electron microscope.
2.5. Measurement of ATPase activity
The ATPase activity of MRP1 was determined as
described previously [40] by using a colorimetric method
to measure the release of inorganic phosphate from ATP.
Typically, 0.5–1.5 Ag of the purified and reconstituted
MRP1 protein was incubated at 37 jC in 0.1 ml assay
buffer containing 50 mM Tris–HCl, pH 7.4, 2 mM ATP,
5 mM MgCl2 for 4 h. The asymmetry of MRP1 incor-
poration was tested by measuring the ATPase activity
difference before and after permeabilization with increas-
ing concentrations of CHAPS, as described previously
[32,40,41].
2.6. Fluorescence quenching assay
Experimental protocols [31,32,37] employed for measur-
ing the phospholipid translocation were adopted. Briefly,
samples were prepared by adding 20 Al of the proteolipo-
somes (50 Ag/ml MRP1) to 430 Al of transport buffer (10
mM Tris–HCl, 250 mM sucrose, and 5 mM MgCl2 (pH
7.4)) in 1.5 ml microfuge tubes. To initiate lipid transport,
50 Al of transport buffer containing ATP and ATP regener-
ation system [32] was added to the proteoliposome samples
(final concentration was 1 mM ATP, 30 Ag/ml creatine
kinase and 3 mM creatine phosphate) and the reaction
mixtures were incubated at 37 jC for the desired length of
time. The sample was then transferred to a 1 ml quartz
cuvette and the fluorescence emission was recorded at 22
jC at F-4010 fluorescence spectrophotometer, using excita-
tion and emission wavelengths of 468 and 540 nm, respec-
tively. After a stable baseline was established, 5 Al of
sodium dithionite solution (final concentration of dithionite
was 10 mM) in 1 M Tris–HCl (pH 10.0) was added to
quench the NBD-PC in the outer leaflet of the proteolipo-
somes. When a new stable line was established, the proteo-
liposomes were permeabilized by adding 50 Al of 10%
Triton X-100 (final concentration was 1%). The fluores-
cence quenching was followed until another new stable line
was established. For control experiments, 50 Al of transport
buffer, instead of ATP, was added.The percentages of NBD-PC quenched by dithionite
(outer leaflet) or protected from dithionite before the Triton
X-100 treatment (inner leaflet) in the proteoliposomes were
calculated by using the following equations.
% Outer leaflet ¼ ½ðFT  FDÞ=ðFT  F0Þ  100
% Inner leaflet ¼ ½ðFD  F0Þ=ðFT  F0Þ  100
Where FT is the total fluorescence of the sample before
addition of dithionite; FD is the fluorescence of the sample
following quenching with dithionite; and F0 is the fluores-
cence of the sample following permeabilization with Triton
X-100. FT, FD and F0 values were derived from the average
of 50 points within the respective stable lines.
2.7. Transport of daunorubicin by the reconstituted MRP1
In order to examine the relationship between the NBD-
PC floppase activity and drug transport activity of the
reconstituted MRP1, daunorubicin uptake into the proteoli-
posomes was determined. The experiments were performed
as follows: 1 Ag of the reconstituted MRP1 was mixed with
daunorubicin (final concentration of 1 AM) and ATP (final
concentration of 1 mM) plus an ATP regenerating system in
a 500 Al of transport buffer mentioned above. After incu-
bation at 22 jC for 40 min, 1 ml of ice-cold transport buffer
was added to stop the reaction. The proteoliposomes were
collected by ultracentrifugation at 145,000 g for 20 min at
4 jC. After removal of the supernatant, the proteoliposomes
were resuspended in 500 Al transport buffer and 0.1% Triton
X-100 (final concentration) was added to release the dau-
norubicin entrapped in the proteoliposomes. The fluores-
cence intensities of the samples were measured immediately
by using an F-4010 fluorescence spectrophotometer with an
excitation and an emission wavelength of 490 and 590 nm at
22 jC.3. Results
3.1. Purification and reconstitution of MRP1
MRP1 protein was purified from BHK cells stably trans-
fected with pNUT/MRP1/His [38] by using His.Bind Resin
column. The purified and reconstituted MRP1 protein was
subjected to SDS-PAGE (7.5% polyacrylamide gel) and
detected by silver staining (Fig. 1, lanes 2 and 3) or Western
blot analysis with MRPr1 antibody (Fig. 1, lanes 4 and 5).
Greater than 90% of the purified proteins were MRP1
protein as judged by densitometry of a silver-stained SDS-
PAGE and approximately 30% of MRP1 protein was
recovered from the reconstitution. The results in lanes 4
and 5 proved that the silver-stained proteins in lanes 2 and 3
were indeed MRP1 protein detected by MRP1-specific
antibody MRPr1.
Fig. 1. Analysis of the purified and reconstituted MRP1 protein. MRP1
proteins in lanes 2 and 3 were detected by silver staining: lane 1, marker;
lane 2, 1 Ag of the purified MRP1 protein; lane 3, 0.2 Ag of the reconstituted
MRP1 protein in the proteoliposomes. Lanes 4 and 5, the purified and
reconstituted MRP1 respectively, were detected by Western blot analysis
using MRPr1 antibody.
Fig. 2. MRP1 protein orientation in the proteoliposomes analyzed by
ATPase activity before and after CHAPS treatment. ATPase assay was
performed according to the method described in Materials and methods.
Proteoliposomes were treated with increased concentrations of CHAPS
indicated in the figure and ATPase activities were determined. Data
(meansF S.E., n= 3) are expressed as the percentage of the control ATPase
activity measured in the absence of CHAPS (100%).
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proteoliposomes is in an inside–out configuration
Since the sealed lipid bilayer vesicle systems are imper-
meable to ATP [32,40–42], only the inside–out oriented
MRP1 protein is expected to interact with ATP. Cryptic
ATPase activity due to inside–in configuration of the Pgp
(with ATP binding domains in the vesicle lumen) should be
exposed to ATP only after detergent permeabilization.
Accordingly, addition of increasing concentrations of the
permeabilizing detergent CHAPS to proteoliposomes con-
taining MRP1 protein resulted in a slight increase (5.6%) in
ATPase activity (Fig. 2), implying that approximately 6% of
the NBDs was prevented from contacting ATP. However,
the treatment with the detergent CHAPS leads to the
inactivation of the protein (Fig. 2), 6% increase of ATPase
activity after treatment with CHAPS might be underesti-
mated. When the activity curve for different CHAPS con-
centrations (Fig. 2) was extrapolated from higher to lower
CHAPS concentrations, a higher percentage (than 6%) of
inside–in oriented protein should be suggested. In any case,
one can make a conclusion that majority of the reconstituted
MRP1 protein in the proteoliposomes is in an inside–out
configuration, which is consistent with previous reports
[42].
3.3. Estimation of the NBD-PC distribution in outer and
inner leaflets
The fluorescence quenching technique we used relies on
the ability of dithionite to quench the fluorescence of NBD-
labeled PC located only in the outer membrane leaflet, dueto the membrane bilayer impermeability [31,32,43]. Initial
experiments were carried out to optimize the dithionite
concentration for efficient quenching of the fluorescence
of NBD-PC in the outer leaflet without affecting the NBD-
PC located in the inner leaflet. A stable baseline could not
be established following addition of 20 mM dithionite,
suggesting that dithionite at that concentration might disturb
the membrane structure and penetrate the bilayer (data not
shown). Stable baselines can be established by using either
2 or 10 mM dithionite. However, when the vesicle samples
were analyzed in the presence of 2 mM dithionite and 1%
Triton X-100, the fluorescence of the samples was not
quenched completely (data not shown), indicating that 2
mM dithionite was not sufficient to quench the fluorescence
of NBD-PC in the proteoliposomes. When the samples were
treated with 10 mM dithionite and 1% Triton X-100, the
fluorescence was quenched completely (to the background
level), therefore, 10 mM dithionite was utilized in the
following experiments.
The dithionite reduction technique depends on the struc-
tural integrity of the membrane system under study. To
observe if the fluorescent NBD-PC lipids affects the integ-
rity of the proteoliposomes, we analyzed and compared the
structural integrity of MRP1 proteoliposomes with or with-
out NBD-PC by electron microscope. The results indicated
that both of the proteoliposomes had the same diameters in
the range of 80–90 nm (Fig. 3). Furthermore, Fig. 4 shows
that stable lines can be established within 10 min after
dithionite treatment in the absence of Triton X-100, whereas
this stable line cannot be established in the presence of
0.01% Triton X-100, implying that the NBD-PC located in
the outer membrane leaflet was quenched completely within
10 min and dithionite cannot penetrate the membrane
Fig. 3. Electron micrographs of negatively stained proteoliposomes. The protocols were described in Materials and methods. (A) MRP1 proteoliposomes
without NBD-PC. (B) MRP1 proteoliposomes with NBD-PC. Bars = 300 nm.
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quenched (calculated using the equations indicated in Mate-
rials and methods) under the condition without ATP, MgCl2Fig. 4. NBD-PC located in the outer membrane leaflet is quenched
completely within 10 min. Proteoliposomes containing MRP1 (1 Ag in 500
Al transport buffer) and NBD-PC (20 ng) were incubated at 37 jC in the
transport buffer with 1 mM ATP and ATP regenerating system for 40 min.
The sample was then transferred to a cuvette and the fluorescence was
measured over time at 22 jC, according to the procedures described in
Materials and methods. After the establishment of the initial stable baseline
( FT), 10 mM dithionite (final concentration) was added to the reaction
mixture. The samples were incubated at 22 jC until a new stable line was
established, then Triton X-100 (final concentration of 1%, w/v) was added
to make the vesicles permeable to dithionite. A stable line was established
after 6–10 min incubation in the absence of detergent, whereas this stable
line cannot be established if 0.01% Triton X-100 was added to the reaction
mixture, indicating that NBD-PC located in the outer membrane leaflet was
quenched completely within 10 min in the absence of Triton X-100. The
fluorescence intensity of the baseline ( FT) was taken as 100%. FD is the
fluorescence intensity of the sample following quenching with dithionite.
F0 is the fluorescence intensity of the sample following the treatment with
detergent Triton X-100.and GSH, implying that 62% of the NBD-PC was localized
in the outer leaflet and the other 38% in the inner leaflet in
the control sample. However, there was a clear decrease in
the amount of NBD-PC in the outer leaflet in the presence of
ATP, MgCl2 and GSH (Fig. 4), presumably the NBD-PC
located in the outer leaflet was translocated to the inner
leaflet by MRP1 in an ATP-dependent manner.
Fig. 5 shows that the re-distribution of NBD-PC to
establish equilibrium between the outer and inner leaflets
by MRP1 in the presence of ATP, MgCl2 and GSH takes
approximately 40–50 min. The maximum amount of NBD-
PC transported from outer to inner leaflet by MRP1 is
approximately 9% (subtracting the amount translocated
without ATP and GSH), which is consistent with the resultsFig. 5. Time course of translocation for NBD-PC in proteoliposomes
containing MRP1. The proteoliposomes were incubated for various times
with 5 mM MgCl2 and 1 mM ATP (and a regenerating system) as well as
2.5 mM GSH, or without ATP and GSH, followed by quenching with
dithionite to determine the transbilayer distribution of the NBD-PC. Data
points represent mean values (F S.E.) of three independent determinations.
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establish the equilibrium between the outer and inner leaf-
lets, the amounts of NBD-PC translocated within 40 min,
for example, 10 min incubation, may be over-estimated due
to the NBD-PC in the outer leaflet cannot be completely
quenched immediately and might be continuously trans-
ported to the inner leaflet during the quenching. However,
after 40 min incubation, the distribution of NBD-PC reachedFig. 7. Effects of the drugs on the reconstituted MRP1 ATPase activity. The
ATPase activity of MRP1 in proteoliposomes was assayed in a reaction
mixture containing 50 mM Tris–HCl, pH 7.4, 2 mM ATP, 5 mM MgCl2
and various drugs, by measuring the release of inorganic phosphate from
ATP, using a colorimetric method adopted from Ref. [39]. The amount of
ATP hydrolyzed without GSH was considered as 100%.equilibrium, and this time, incubation is used in the follow-
ing experiments.
3.4. Translocation of NBD-PC by MRP1 is ATP-, Mg2+-
and GSH-dependent
Fig. 4 shows that 38% of NBD-PC was located in the
inner leaflet of the bilayer in the absence of ATP, MgCl2 and
GSH, however, the amount of NBD-PC in the inner leaflet
was significantly increased in the presence of these com-
pounds. We were curious whether the translocation of NBD-
PC by MRP1 required all three compounds or only one of
them. Fig. 6A(a) shows that the amount of NBD-PC in the
inner leaflet of the bilayer was increased from 38% to 47%
in the presence of all three compounds, whereas the trans-
location of NBD-PC in the absence of either GSH (Fig.
6A(b)), ATP (Fig. 6A(c)) or MgCl2 (Fig. 6A(d)) was
inhibited completely. In addition, 86% of the translocation
was inhibited by 100 AM MK571 (Fig. 6B(d)), a potent
MRP1 inhibitor [44]; 56% by 500 AM vanadate (Fig.
6B(c)), a non-specific ATPase inhibitor which traps the
ATP hydrolysis product ADP at the nucleotide binding site;Fig. 6. The effects of ligands, substrates and inhibitors on the translocation
of NBD-PC. Transbilayer distribution of NBD-PC in the reconstituted
MRP1 proteoliposomes was determined by fluorescence quenching with
dithionite under the conditions indicated in the figure. Experiments were
performed in triplicate and the data represent the mean values (F S.E.).
A(a), 1 mM ATP (and a regenerating system), 2.5 mM GSH and 5 mM
MgCl2; (b), 1 mM ATP (and a regenerating system) and 5 mM MgCl2,
without 2.5 mM GSH; (c), 2.5 mM GSH and 5 mM MgCl2, without ATP;
(d), 1 mM ATP and 2.5 mM GSH, without MgCl2. B(a), 1 mM ATP (and a
regenerating system), 2.5 mM GSH and 5 mM MgCl2; as well as 1 mM
verapamil (b), 500 AM vanadate (c), or 100 AM MK571 (d). C, 1 mM ATP
(and an ATP regenerating system), 5 mM MgCl2, and 2.5 mM GSH (b) as
well as the indicated compounds (a, c, d, e, f, g).
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inhibited LTC4 transport by MRP1 [45]. To test whether
other substrates, such as anticancer drugs, should also
inhibit the translocation of the NBD-PC, the experiments
were performed in the presence of ATP, MgCl2, GSH and
individual substrate. Fig. 6C shows that the translocation of
NBD-PC in the presence of 30 AM vincristine (Fig. 6C(c)),
30 AM vinblastine (Fig. 6C(d)), 30 AM daunorubicin (Fig.
6C(e)), 30 AM doxorubicin (Fig. 6C(f)) and 500 AM
oxidized glutathione (GSSG) (Fig. 6C(g)) was inhibited
45%, 24%, 54%, 34% and 64%, respectively. Whether
those inhibitions are competitive or non-competitive are
not known yet. However, when the MRP1 ATPase activities
were analyzed under the same conditions in the presence of
30 AM vincristine (c), 30 AM vinblastine (d), 30 AM
daunorubicin (e), 30 AM doxorubicin (f) and 500 AM GSSG            
   
 
   
  
Fig. 8. Daunorubicin transported by the reconstituted MRP1 proteolipo-
somes. The experiments were performed according to the protocol
described in Materials and methods. Data represent the mean values
(F S.E.) of triplicate determinations and the amount of daunorubicin
transported in the presence of ATP and GSH was considered as 100%. A(a),
1 mM ATP with an ATP regenerating system, 2.5 mM GSH and 5 mM
MgCl2; (b), 1 mM ATP with an ATP regenerating system and 5 mMMgCl2,
without GSH; (c), 2.5 mM GSH and 5 mMMgCl2, without ATP; (d), 1 mM
ATP with an ATP regenerating system and 2.5 mM GSH, without MgCl2.
B, 1 mM ATP with an ATP regenerating system and 5 mM MgCl2, as well
as the compounds indicated in the figure (a, c, d, e, f, g).(g), the ATPase activities were increased 28%, 18%, 26%,
19% and 50%, respectively (Fig. 7). The trend of translo-
cation inhibition by these compounds is consistent with the
trend of ATPase activity stimulation, implying that one
MRP1 molecule cannot translocate an anticancer drug
molecule and an NBD-PC lipid at the same time.
3.5. Translocation of daunorubicin by MRP1 is facilitated
by ATP, Mg2+ and GSH
To test whether the translocation of an anticancer drug by
the reconstituted MRP1 in the proteoliposomes is also ATP-,
Mg2 +- and GSH-dependent, the experiments were per-
formed in the presence or absence of either ATP, Mg2 + or
GSH. The fluorescence intensity of daunorubicin trans-
ported by the reconstituted MRP1 in the presence of ATP
(with an ATP regenerating system), 2.5 mM GSH and 5 mM
MgCl2 was taken as 100% (Fig. 8A(a)). The fluorescence
intensities of daunorubicin transported into the proteolipo-
somes in the absence of GSH, ATP or MgCl2 decreased to
80% (Fig. 8A(b)), 78% (Fig. 8A(c)) and 74% (Fig. 8A(d)),
respectively. This 74–80% translocation in the absence of
either GSH, ATP or MgCl2 might reflect the hydrophobic
compound daunorubicin inserted into the proteoliposomes.
Therefore, the insertion of daunorubicin into the MRP1-
reconstituted proteoliposomes is facilitated by the presence
of ATP, Mg2 + and GSH. This ATP-dependent daunorubicin
transport can be partially inhibited by other MRP1 sub-
strates, such as vincristine (Fig. 8B(c)), vinblastine (Fig.
8B(d)), doxorubicin (Fig. 8B(e)) or GSSG (Fig. 8B(f)).4. Discussion
MRP1 protein is ubiquitously expressed in normal tis-
sues [46]. What is the function of the MRP1 protein in those
tissues? MRP1 protein has been found to transport anionic
conjugates, including glutathione-, glucuronate- or sulfate-
conjugated aliphatic, prostanoid or heterocyclic compounds
[15–23]. These hydrophobic aliphatic, prostanoid or het-
erocyclic compounds may come from food, herbicides,
tobacco-related products or chemotherapeutic agents and
are toxic to the cells. The active efflux of these potentially
toxic compounds by MRP1 protein is generally an impor-
tant aspect of cellular detoxification [47]. Does MRP1
protein have another common function in all these normal
tissues? MRP1 has been postulated to function as a floppase
in cells to translocate the phospholipids in membrane
bilayer [36]. Red blood cells derived from knockout mice
for Mrp1 (Mrp / ) lost the ability to translocate fluores-
cent-labeled phospholipids NBD-PC and NBD-PS [33],
hinting that MRP1 protein is responsible for the observed
flop of the fluorescent lipid analogues. The inhibitory
effects of various anticancer drugs, glutathione-conjugates
and oxidized GSSG on the flop of the fluorescent-labeled
NBD-PS closely correlated with those reported for active
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MRP1 protein functions as a floppase on the plasma
membrane of the erythrocyte [34]. LLC-PK1 pig kidney
epithelial cells transfected with human MRP cDNA gained
the ability to specifically translocate C6-NBD-glucosylcer-
amide and C6-NBD-sphingomyelin [35], also implying that
MRP1 protein translocates those lipids. However, all these
results derived from intact cells provide indirect evidences
showing that MRP1 protein may function as a floppase to
translocate the phospholipids from inner to outer leaflet.
Here we proved that the majority of the purified MRP1
protein was reconstituted into proteoliposomes in an inside–
out configuration (Fig. 2) and translocated the fluorescent-
labeled PC from outer to inner leaflet (Figs. 4 and 5), which
is consistent with the results derived from intact cells that
translocated the fluorescent-labeled lipids from inner to
outer leaflet [34,35]. Therefore, we provide direct evidence
that the purified and reconstituted human MRP1 protein
functions as a floppase to translocate the fluorescent-labeled
NBD-PC. The translocation requires ATP and MgCl2 (Fig.
6A), indicating that MRP1 protein couples ATP binding/
hydrolysis to the translocation of the phospholipid analogue.
Vanadate, a non-specific ATPase inhibitor which traps ATP
hydrolysis product ADP at the ATP binding site, inhibits the
translocation of the NBD-PC (Fig. 6B), further supporting
the conclusion that translocation of NBD-PC requires ATP
hydrolysis. In addition, the translocation is GSH-dependent
(Fig. 6A(b)), sharing the same mechanism to transport
anticancer drugs [18]. Whether NBD-PC occupies the same
solute binding site as those anticancer drugs is not clear yet.
Although those anticancer drugs, such as vincristine, vin-
blastine, daunorubicin and doxorubicin, more or less inhibit
the translocation of NBD-PC (Fig. 6C), the results do not
prove directly that NBD-PC and the anticancer drugs
occupy the same binding site. However, since translocations
of both anticancer drugs and phospholipids are GSH- and
ATP hydrolysis-dependent (Figs. 6 and 8), no matter wheth-
er they occupy the same or different binding sites, the
transport of those anticancer drugs should more or less
inhibit the translocation of the phospholipids. Consistent
with this conclusion, the MRP1 substrate GSSG [48] also
inhibits the translocation of NBD-PC (Fig. 6C). In addition,
MK-571, a potent MRP1 inhibitor known to specifically
reverse MRP1-mediated anticancer drug resistance [44],
inhibits the NBD-PC translocation almost completely (Fig.
6B(d)). All these results support the notion that MRP1
protein possesses the ability to translocate the PC analogue
in the membrane bilayer where the protein resides and this
may be another important physiological function of MRP1
protein to re-distribute the phospholipids in the plasma
membrane bilayer. However, since the substrate we used
in the experiments is a fluorescent-labeled phosphatidylcho-
line analogue, it might not reflect that of the native lipids,
but might merely reflect the recognition of NBD-PC as
xenobiotics by MRP1 protein. It has been noticed that the
PC analogue, NBD-PC, is more easily transferred betweenmembranes than native PC [31,37,43,49]. However, NBD-
phosphatidylethanolamine, another NBD-labeled phospho-
lipid, is not translocated by MRP1 protein in the same
MRP1-reconstituted proteoliposomes (data not shown), im-
plying that MRP1 protein recognizes the phosphatidylcho-
line backbone rather than the NBD. Therefore, although
NBD-PC is not a native phospholipid, our results do prove
that MRP1 protein recognizes phospholipid backbone and
translocates them to another leaflet.Acknowledgements
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